Department of Neurosurgery, Shandong Provincial Hospital, Shandong University, No.324 Jingwu Rd, Jinan, 250021, People's Republic of China.
Department of Neurosurgery, Qilu Hospital, Shandong University, No.107 Wenhuaxi Rd, Jinan, 250012, People's Republic of China.
Mol Neurobiol. 2016 Apr;53(3):1452-1460. doi: 10.1007/s12035-014-9079-9. Epub 2015 Jan 31.
Glioma, the most common type of primary central nervous system cancers, was progressive with poor survival. MicroRNA, as a novel biomarker, was suspected to be novel biomarkers for glioma diagnosis and prognosis. The study aimed at investigating the diagnostic and predictive value of miR-221/222 family for glioma. In the first phase, we compared plasma miR-221/222 family levels between 50 glioma patients and 51 healthy controls by real-time qRT-PCR amplification. Meanwhile, a meta-analysis based on published studies and presents study was performed to explore the diagnostic performance of miR-221/222 family in human cancers. In the second phase, we correlated the miR-221/222 family expression level with prognosis of glioma using Kaplan-Meier survival curves. The plasma miR-221/222 family levels were found to be significantly upregulated in glioma patients (P = 0.001). The ROC curve analysis yielded an AUC values of 0.84 (95% confidence interval (CI): 0.74-0.93) for miR-221 and 0.92 (95% CI 0.87-0.94) for miR-222. In the meta-analysis, the summary receiver operating characteristic (sROC) was plotted with an AUC of 0.82 (95% CI 0.78-0.85) for miR-221/222 family. It was also demonstrated that high positive plasma miR-221 and miR-222 were both correlated with poor survival rate (miR-221: HR = 2.13; 95% CI, 1.05-4.31; miR-222: HR = 2.09; 95% CI, 1.00-4.37). This study demonstrated that the detection of the miRNA-221/222 family should be considered as a new additional tool to better characterize glioma.
神经胶质瘤是中枢神经系统最常见的原发性癌症，呈进行性发展，生存预后较差。微小 RNA 作为一种新型生物标志物，被怀疑是神经胶质瘤诊断和预后的新型生物标志物。本研究旨在探讨 miR-221/222 家族对神经胶质瘤的诊断和预测价值。在第一阶段，我们通过实时 qRT-PCR 扩增比较了 50 例神经胶质瘤患者和 51 例健康对照者血浆 miR-221/222 家族水平。同时，基于已发表的研究和本研究进行了荟萃分析，以探讨 miR-221/222 家族在人类癌症中的诊断性能。在第二阶段，我们通过 Kaplan-Meier 生存曲线将 miR-221/222 家族表达水平与神经胶质瘤的预后相关联。结果发现，神经胶质瘤患者的血浆 miR-221/222 家族水平明显上调（P = 0.001）。ROC 曲线分析得出 miR-221 的 AUC 值为 0.84（95%置信区间（CI）：0.74-0.93），miR-222 的 AUC 值为 0.92（95% CI 0.87-0.94）。荟萃分析中，绘制了汇总受试者工作特征（sROC）曲线，miR-221/222 家族的 AUC 为 0.82（95% CI 0.78-0.85）。研究还表明，高阳性血浆 miR-221 和 miR-222 均与生存率降低相关（miR-221：HR = 2.13；95% CI，1.05-4.31；miR-222：HR = 2.09；95% CI，1.00-4.37）。本研究表明，miR-221/222 家族的检测可被视为更好地描述神经胶质瘤的一种新的附加工具。
